Literature DB >> 1649324

SL3-3 enhancer factor 1 transcriptional activators are required for tumor formation by SL3-3 murine leukemia virus.

B Hallberg1, J Schmidt, A Luz, F S Pedersen, T Grundström.   

Abstract

The transcriptional enhancers of retroviruses that lack an oncogene are important determinants of their oncogenicity. However, no specific cellular transcriptional activator has yet been found to determine the oncogenicity for any of these viruses. The SL3-3 enhancer factor 1 (SEF1) cellular transcriptional activators are expressed preferentially in T lymphocytes. In the SL3-3 murine leukemia virus enhancer, two different sequences can bind SEF1 activators. We show that mutation of the SEF1 binding sites disrupts the disease potential of SL3-3 murine leukemia virus, implying that SEF1 transcriptional activators are required for tumor induction by SL3-3. The SEF1 site mutations did not appear to affect the pathogenicity of SL3-3 by impairment of virus multiplication, but rather by a specific defect in the ability of neoplastic transformation.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1649324      PMCID： PMC248852     

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  26 in total

1.  A plaque assay for murine leukemia virus using enzyme-coupled antibodies.

Authors:  B A Nexo
Journal:  Virology       Date:  1977-04       Impact factor: 3.616

2.  Binding of SL3-3 enhancer factor 1 transcriptional activators to viral and chromosomal enhancer sequences.

Authors:  A Thornell; B Hallberg; T Grundström
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

3.  Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia.

Authors:  R K Saiki; S Scharf; F Faloona; K B Mullis; G T Horn; H A Erlich; N Arnheim
Journal:  Science       Date:  1985-12-20       Impact factor: 47.728

4.  Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase.

Authors:  R K Saiki; D H Gelfand; S Stoffel; S J Scharf; R Higuchi; G T Horn; K B Mullis; H A Erlich
Journal:  Science       Date:  1988-01-29       Impact factor: 47.728

5.  A new technique for the assay of infectivity of human adenovirus 5 DNA.

Authors:  F L Graham; A J van der Eb
Journal:  Virology       Date:  1973-04       Impact factor: 3.616

6.  Differential protein binding in lymphocytes to a sequence in the enhancer of the mouse retrovirus SL3-3.

Authors:  A Thornell; B Hallberg; T Grundström
Journal:  Mol Cell Biol       Date:  1988-04       Impact factor: 4.272

7.  Novel leukaemogenic retroviruses isolated from cell line derived from spontaneous AKR tumour.

Authors:  F S Pedersen; R L Crowther; D Y Tenney; A M Reimold; W A Haseltine
Journal:  Nature       Date:  1981-07-09       Impact factor: 49.962

8.  Different relative expression from two murine leukemia virus long terminal repeats in unintegrated transfected DNA and in integrated retroviral vector proviruses.

Authors:  K Paludan; H Y Dai; M Duch; P Jørgensen; N O Kjeldgaard; F S Pedersen
Journal:  J Virol       Date:  1989-12       Impact factor: 5.103

9.  Type C RNA tumor virus isolated from cultured human acute myelogenous leukemia cells.

Authors:  R E Gallagher; R C Gallo
Journal:  Science       Date:  1975-01-31       Impact factor: 47.728

10.  A common region for proviral DNA integration in MoMuLV-induced rat thymic lymphomas.

Authors:  P N Tsichlis; P G Strauss; L F Hu
Journal:  Nature       Date:  1983 Mar 31-Apr 6       Impact factor: 49.962
View more
  58 in total

1.  Selection of reversions and suppressors of a mutation in the CBF binding site of a lymphomagenic retrovirus.

Authors:  M J Martiney; K Rulli; R Beaty; L S Levy; J Lenz
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

2.  Sequences between the enhancer and promoter in the long terminal repeat affect murine leukemia virus pathogenicity and replication in the thymus.

Authors:  F K Yoshimura; T Wang; M Cankovic
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

3.  Disruption of hematopoiesis and thymopoiesis in the early premalignant stages of infection with SL3-3 murine leukemia virus.

Authors:  Karen Rulli; Jack Lenz; Laura S Levy
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

4.  Molecular and phylogenetic analysis of SRS 19-6 murine leukemia virus.

Authors:  L M Bundy; H Fan
Journal:  Virus Genes       Date:  1999       Impact factor: 2.332

5.  Contributions to transcriptional activity and to viral leukemogenicity made by sequences within and downstream of the MCF13 murine leukemia virus enhancer.

Authors:  J C Tupper; H Chen; E F Hays; G C Bristol; F K Yoshimura
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

6.  AML1 is expressed in skeletal muscle and is regulated by innervation.

Authors:  X Zhu; J E Yeadon; S J Burden
Journal:  Mol Cell Biol       Date:  1994-12       Impact factor: 4.272

7.  Pathogenic determinants in the U3 region of recombinant murine leukemia viruses isolated from CWD and HRS/J mice.

Authors:  S C Lawrenz-Smith; A C Massey; D J Innes; C Y Thomas
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

8.  Origins of enhancer sequences of recombinant murine leukemia viruses from spontaneous B- and T-cell lymphomas of CWD mice.

Authors:  A C Massey; S C Lawrenz-Smith; D J Innes; C Y Thomas
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

9.  Transcriptional activity of core binding factor-alpha (AML1) and beta subunits on murine leukemia virus enhancer cores.

Authors:  A L Zaiman; A F Lewis; B E Crute; N A Speck; J Lenz
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

10.  Cloning and characterization of subunits of the T-cell receptor and murine leukemia virus enhancer core-binding factor.

Authors:  S Wang; Q Wang; B E Crute; I N Melnikova; S R Keller; N A Speck
Journal:  Mol Cell Biol       Date:  1993-06       Impact factor: 4.272
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.